Active Filter(s):
Details:
XenoTherapeutics has completed the first of two patient cohorts in the company’s Phase I trial of Xeno-Skin™, first-in-human, live-cell xenotransplant to treat severe and extensive burn wounds. As a result, the U.S. FDA has agreed to permit accelerated patient enrollment.
Lead Product(s): Xeno-Skin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Xeno-Skin
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020